Post-market, Prospective, Randomised, Sham-controlled Clinical Trial Designed to Confirm the Efficacy and Safety of the Fotona Smooth® Device to Treat Female Stress Urinary Incontinence
试验速览
- 阶段
- 不适用
- 入组人数
- 135
- 试验地点
- 9
- 主要终点
- Safety: Incidence and severity of device related Adverse Events
研究概览
简要总结
There are many existing treatments of female stress urinary incontinence such as the use of adult absorbent pads and diapers, behavioral training, including bladder training, pelvic muscle exercises, biofeedback, urethral plugs, intravaginal prosthesis, electrical stimulation, periurethral injections, and reconstructive surgery. However, there is still a lack of effective minimally invasive treatment options that are independent of patient compliance.
One emerging approach of minimally invasive SUI therapy is pelvic floor reinforcement using laser therapy.
The primary objective of this post-marketing study is to confirm the effectiveness and safety of the FotonaSmooth® device in the treatment of stress urinary incontinence (SUI) in a large number of females using objective and subjective methods.
Patients with stress incontinence will be assigned to two groups, an active group, where the Fotona Dynamis Er:YAG Laser System will be used, and a sham group where a very low laser setting will be used, and parameter presentations will be masked.
Participants will be adult females, 18 years old and older with clinical and urodynamic diagnosis of Stress Urinary Incontinence,who have had no significant improvement in urinary incontinence from at least one previous conservative treatment, such as behavioral measures, pelvic floor muscle training or the use of absorbent pads
详细描述
Prospective, randomized, 2-treatment, sham-controlled, single (patient only) blinded, study design using convenience sampling to enroll subjects as they present and are found to be eligible per the inclusion/exclusion criteria. This multicenter clinical trial utilizes a randomized assignment allocation schedule stratified by clinical site. Allocation rule pertains to the ratio of subjects in each treatment arm. Sampling rules pertain to the number of subjects in each active treatment arm.
Two treatment arms enrolled on a 2:1 ratio: Active arm is the Fotona Dynamis Er:YAG Laser System and the control arm is a sham treatment with a very low laser setting and parameter presentations masked. The active arm subjects will be followed out to 12 months post-treatment. The sham arm subjects will be followed out to 6 months and then offered the active treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Adult Female, 18 years of age or older,
- •Clinical and UDS diagnosis of Stress Urinary Incontinence,
- •No significant improvement in urinary incontinence from at least one previous conservative treatments, such as behavioral measures, pelvic floor muscle training or the use of absorbent pads
排除标准
- •Pre-existing bladder pathology including prior radiation treatment
- •Radical pelvic surgery or previous incontinence surgery
- •Urinary tract infection or other active infections of urinary tract or bladder
- •Endometriosis
- •Any form of pelvic organ prolapse greater than stage 2, according to POP-Q
- •Diagnosis of urge incontinence
- •Diagnosis of collagen disorders e.g. benign joint hypermobility / Elhers-Danlos / Marfans etc.
- •Incomplete bladder emptying
- •Vesicovaginal fistula
- •Fecal incontinence
- •Unwillingness or inability to complete follow-up schedule
- •Unwillingness or inability to give Informed Consent
- •Failure to comply with diary requirements during extended baseline period
研究组 & 干预措施
Fotona Dynamis Er:YAG Laser System
Active treatment with Fotona Dynamis Er:YAG Laser System
干预措施: Fotona Dynamis Er:YAG Laser System (Device)
Fotona Dynamis Er:YAG Laser System with Sham handpience
Sham treatment with a sham handpiece and parameter presentations masked
干预措施: Fotona Dynamis Er:YAG Laser System with sham handpience (Device)
结局指标
主要结局
Safety: Incidence and severity of device related Adverse Events
时间窗: 6 months post-treatment
Incidence and severity of device related Adverse Events (i.e., infections, edema, superficial burns, increased vaginal discharge, de novo urge incontinence).
Efficacy: Reduction in 1-hour pad weight between active and sham groups
时间窗: 6 months post-treatment
Reduction in 1-hour pad weight at 6 months post-treatment in active group vs the sham treated group at 6 months post treatment
次要结局
- Change in mean PISQ-12 test scores(from baseline to 6 and 12 months post-treatment.)
- Durability of the effect(12 months post-treatment)
- Change in King's Health Questionnaire (KHQ)(from baseline to 6 and 12 months post-treatment.)
- Subjective assessment of pain(6 months)
- Improvement(6 and 12 months post-treatment)
- Change in International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) score(from baseline to 6 and 12 months post-treatment.)
研究者
Barry O'Reilly
Professor
Cork University Hospital
